Adagene Inc.
Index- P/E- EPS (ttm)-1.85 Insider Own10.61% Shs Outstand43.64M Perf Week-0.71%
Market Cap124.12M Forward P/E- EPS next Y-2.44 Insider Trans0.00% Shs Float17.58M Perf Month-23.29%
Income-73.20M PEG- EPS next Q-0.67 Inst Own19.40% Short Float0.43% Perf Quarter-48.53%
Sales10.20M P/S12.17 EPS this Y-50.50% Inst Trans-0.14% Short Ratio1.87 Perf Half Y-67.78%
Book/sh3.59 P/B0.78 EPS next Y-41.90% ROA-50.40% Target Price24.69 Perf Year-77.95%
Cash/sh3.93 P/C0.71 EPS next 5Y- ROE-167.80% 52W Range2.76 - 20.98 Perf YTD-65.30%
Dividend- P/FCF- EPS past 5Y- ROI-45.10% 52W High-86.65% Beta-
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low1.63% ATR0.18
Employees259 Current Ratio6.20 Sales Q/Q1026.20% Oper. Margin- RSI (14)25.36 Volatility4.66% 6.11%
OptionableNo Debt/Eq0.05 EPS Q/Q-643.80% Profit Margin- Rel Volume0.71 Prev Close2.82
ShortableYes LT Debt/Eq0.02 EarningsMar 31 BMO Payout- Avg Volume40.77K Price2.80
Recom1.70 SMA20-10.53% SMA50-21.87% SMA200-67.99% Volume29,143 Change-0.71%
Jun-25-21Initiated China Renaissance Buy $40.57
Mar-08-21Initiated Morgan Stanley Overweight $34
Mar-08-21Initiated Jefferies Buy $33
Mar-08-21Initiated Goldman Buy $29
May-26-22 09:30PM  
May-12-22 07:00AM  
May-02-22 06:06AM  
Apr-08-22 01:09PM  
Apr-03-22 02:34PM  
Mar-31-22 08:30AM  
Mar-17-22 10:42AM  
Mar-16-22 10:00AM  
Mar-08-22 09:21PM  
Mar-02-22 08:22AM  
Feb-08-22 07:00AM  
Feb-02-22 04:05PM  
Jan-27-22 07:00AM  
Jan-19-22 07:00AM  
Jan-13-22 04:00AM  
Dec-22-21 04:05PM  
Dec-13-21 10:23AM  
Dec-06-21 01:49PM  
Nov-30-21 04:01PM  
Nov-29-21 04:05PM  
Nov-22-21 05:05PM  
Nov-09-21 04:05PM  
Nov-04-21 09:24AM  
Oct-27-21 08:52AM  
Oct-21-21 08:00AM  
Sep-17-21 12:22PM  
Sep-02-21 07:45AM  
Aug-26-21 07:45AM  
Aug-19-21 07:37AM  
Aug-12-21 07:45AM  
Jul-22-21 07:45AM  
Jul-12-21 10:15PM  
Jul-09-21 10:47AM  
Jul-07-21 07:45AM  
Jun-16-21 04:49PM  
May-25-21 04:05PM  
May-19-21 05:05PM  
Apr-13-21 07:45AM  
Mar-31-21 07:45AM  
Mar-29-21 07:45AM  
Mar-16-21 08:05AM  
Feb-11-21 10:08AM  
Feb-09-21 05:18PM  
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.